Literature DB >> 23146868

Clinical features, surgical treatment and long-term outcome in adult patients with Moyamoya disease in China.

Xiang-Yang Bao1, Lian Duan, De-Sheng Li, Wei-Zhong Yang, Wei-Jian Sun, Zheng-Shan Zhang, Rui Zong, Cong Han.   

Abstract

BACKGROUND: Moyamoya disease (MMD) develops mostly in Asian countries including Japan, Korea, mainland China and Taiwan. However, there are few detailed demographic and clinical data about Chinese patients with MMD. Currently, the most effective treatment in adult patients with MMD is unknown. There have only been a few small case series reporting on encephaloduroarteriosynangiosis (EDAS) in an adult population. Here we describe the clinical features, surgical treatment and long-term outcome of adults with MMD treated at a single institution in China.
METHODS: Our cohort included 470 adult patients with MMD. The demographic and clinical characteristics were obtained by retrospective chart review and long-term outcome was evaluated using the stroke status. The modified Rankin Scale (mRS) was used to determine the neurological functional outcome. Univariate and multivariate logistic regression analyses were performed to determine risk factors for postoperative morbidity and functional outcome. The risk of subsequent stroke was determined using the Kaplan-Meier method and Cox regression was used to determine risk factors for postoperative or subsequent strokes.
RESULTS: The median age for the onset of symptoms was 36.8 (range, 18-59) years. The ratio of female to male patients was 1:1 (231/239). Familial occurrence of MMD was 2.3%. The most common initial symptom was a cerebral ischemic event. The incidence of postoperative ischemic events or hemorrhage was 5.9% (9.8% of patients). Older age at symptom onset, posterior cerebral artery (PCA) involvement and the presence of transient ischemic attack (TIA) were identified as predictors of adverse postoperative events. The Kaplan-Meier estimate stroke risk was 10.1% in the first 2 years, and the 5-year Kaplan-Meier risk of stroke was 13% after surgery for all patients treated with surgical revascularization. Older age at symptom onset, PCA involvement and the presence of TIA were identified as predictors of postoperative or subsequent strokes. Overall, 73.2% of patients had an independent life with no significant disability, with the strongest predictor being the preoperative mRS score.
CONCLUSION: Clinical characteristics of adult MMD in China are different from those in other Asian countries. EDAS in adult patients with MMD carries a low risk, is effective at preventing future ischemic events and improves quality of life.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2012        PMID: 23146868     DOI: 10.1159/000343225

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  13 in total

1.  Moyamoya syndrome associated with Graves' disease: a case series study.

Authors:  Jun Ni; Li-Xin Zhou; Yan-Ping Wei; Ming-Li Li; Wei-Hai Xu; Shan Gao; Li-Ying Cui
Journal:  Ann Transl Med       Date:  2014-08

2.  Cerebrovascular collaterals correlate with disease severity in adult North American patients with Moyamoya disease.

Authors:  M K Strother; M D Anderson; R J Singer; L Du; R D Moore; Y Shyr; T R Ladner; D Arteaga; M A Day; P F Clemmons; M J Donahue
Journal:  AJNR Am J Neuroradiol       Date:  2014-03-20       Impact factor: 3.825

3.  High variance of intraoperative blood pressure predicts early cerebral infarction after revascularization surgery in patients with Moyamoya disease.

Authors:  Jiaxi Li; Yahui Zhao; Meng Zhao; Penghui Cao; Xingju Liu; Hao Ren; Dong Zhang; Yan Zhang; Rong Wang; Jizong Zhao
Journal:  Neurosurg Rev       Date:  2019-06-15       Impact factor: 3.042

Review 4.  Surgical Treatment of Adult Moyamoya Disease.

Authors:  Si Un Lee; Chang Wan Oh; O-Ki Kwon; Jae Seung Bang; Seung Pil Ban; Hyoung Soo Byoun; Tackeun Kim
Journal:  Curr Treat Options Neurol       Date:  2018-05-28       Impact factor: 3.598

Review 5.  Recent advances in moyamoya disease: pathophysiology and treatment.

Authors:  Annick Kronenburg; Kees P J Braun; Albert van der Zwan; Catharina J M Klijn
Journal:  Curr Neurol Neurosci Rep       Date:  2014-01       Impact factor: 5.081

Review 6.  Basal and Acetazolamide Brain Perfusion SPECT in Internal Carotid Artery Stenosis.

Authors:  Teck Huat Wong; Qaid Ahmed Shagera; Hyun Gee Ryoo; Seunggyun Ha; Dong Soo Lee
Journal:  Nucl Med Mol Imaging       Date:  2020-01-08

7.  Endothelial Progenitor Cells Induce Angiogenesis: a Potential Mechanism Underlying Neovascularization in Encephaloduroarteriosynangiosis.

Authors:  Qian-Nan Wang; Zheng-Xing Zou; Xiao-Peng Wang; Qian Zhang; Ya-Qun Zhao; Lian Duan; Xiang-Yang Bao
Journal:  Transl Stroke Res       Date:  2020-07-06       Impact factor: 6.829

Review 8.  Moyamoya Disease: Treatment and Outcomes.

Authors:  Tackeun Kim; Chang Wan Oh; Jae Seung Bang; Jeong Eun Kim; Won-Sang Cho
Journal:  J Stroke       Date:  2016-01-29       Impact factor: 6.967

9.  The Contrast Enhancement of Intracranial Arterial Wall on High-resolution MRI and Its Clinical Relevance in Patients with Moyamoya Vasculopathy.

Authors:  Maoxue Wang; Yongbo Yang; Fei Zhou; Ming Li; Renyuan Liu; Maobin Guan; Rui Li; Le He; Yun Xu; Bing Zhang; Bin Zhu; Xihai Zhao
Journal:  Sci Rep       Date:  2017-03-09       Impact factor: 4.379

Review 10.  Characteristics of Moyamoya Disease in the Older Population: Is It Possible to Define a Typical Presentation and Optimal Therapeutical Management?

Authors:  Ignazio G Vetrano; Anna Bersano; Isabella Canavero; Francesco Restelli; Gabriella Raccuia; Elisa F Ciceri; Giuseppe Faragò; Andrea Gioppo; Morgan Broggi; Marco Schiariti; Laura Gatti; Paolo Ferroli; Francesco Acerbi
Journal:  J Clin Med       Date:  2021-05-25       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.